I joined the company in June 2023, shortly before it went public on NASDAQ in September. It was a 70-person medical device start-up—pre-commercial, grant-funded, but fully subject to SEC regulations. The primary challenge was extending the cash runway as much as possible. I led long-range planning twice a year, navigating shifting timelines for FDA De Novo submission and subsequent commercialization.
In this role, I wore multiple hats across the organization, including internal controls, 13-week cash forecasting, project controlling, NetSuite and Concur administration, ADP practitioner responsibilities, monthly board reporting, budgeting, and quarterly forecasting. Essentially, if it needed to be done, I took it on.
Ultimately, cash flow uncertainty—compounded by a government shutdown—led to a headcount reduction, marking another challenging but highly instructive chapter in my career.
Dallas, TX